Share

Amarin CEO comments on its new medicine's mixed results in its drug trial

CNBC's Meg Tirrell sits down with Amarin CEO John Thero to discuss Amarin dropping after posting mixed results in a drug trial.
03:29
Mon, Nov 12 201812:39 PM EST